Follicular growth and development under continuous gonadotropin-releasing hormone antagonist administration.
OBJECTIVE
Ovarian follicle and cyst formation have been recognized as an advance phenomenon associated with GnRH agonist administration. With the use of GnRH antagonists, pituitary suppression is immediate and no flare effect and follicle growth are expected. We describe two patients who developed a dominant follicle and presumably ovulated in response to hCG triggering under continuous sole administration of a GnRH antagonist.


METHODS
Case report.


METHODS
An IVF unit at a university hospital.


METHODS
Two young healthy female patients undergoing IVF because of male-factor infertility.


METHODS
Continuous daily administration of a GnRH antagonist from menstruation with the aim of achieving ovarian suppression.


METHODS
Endocrine and ultrasound characteristics of follicular growth.


RESULTS
Both patients developed a dominant follicle under sole administration of a GnRH antagonist, accompanied by a gradual rise in serum estradiol and endometrial thickness which culminated in a spontaneous LH surge. Ovulation was triggered by hCG and mid-luteal progesterone levels were suggestive of ovulation.


CONCLUSIONS
We describe for the first time the development of a dominant follicle and presumable ovulation under continuous administration of a GnRH antagonist. Serum gonadotropin concentrations indicate that the pituitary failed to suppress in both patients. The exact mechanism of this phenomenon remains to be elucidated.
Weissman
Ariel
A
Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Tel Aviv University, Tel Aviv, Israel. a_w@zahav.net.il
Ravhon
Amir
A
Biran
Galia
G
Levin
Dan
D
Golan
Abraham
A
Levran
David
D
D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors*; D006801:Humans; D007231:Infant, Newborn; D007248:Infertility, Male / Q000628:therapy; D008297:Male; D006080:Ovarian Follicle / Q000187:drug effects* / Q000254:growth & development*; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D011256:Pregnancy Outcome
D007987:Gonadotropin-Releasing Hormone; C062876:cetrorelix